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論文の内容の要旨 
Abstract of Thesis 
[Purpose] The standard treatment for locally advanced cervical cancer is cisplatin-based concurrent 
chemoradiotherapy (CCRT). On the other hand, PIK3CA gene is closely related with cancer including cervical cancer. 
Mutations of the PIK3CA gene are associated with poor prognosis in patients with different solid tumors of different 
organs, but they can lead to a favorable response to PI3-kinase/AKT inhibitors. Moreover, the PI3-
kinase/AKT/mTOR is the most commonly activated pathway in human cancer, present in 30-50% of all tumors. 
PIK3CA mutations and modification of p110α are reported to be the most frequent driver mutations in cancer. 
Although the activated PI3-kinase/AKT pathway is known to be involved in both cisplatin-resistance and 
radioresistance, to date only a few studies have reported significant associations between PIK3CA gene mutational 
status and outcome by CCRT in the disease. The aim of this study was to clarify the prognostic significance of 
PIK3CA mutational status in cervical cancers treated by CCRT.  
[Materials and Methods]  The author analyzed PIK3CA mutation in 59 patients diagnosed with stages IIB to IVA 
cervical carcinomas primarily treated by CCRT with weekly cisplatin at our institution. She used formalin-fixed 
paraffin-embedded biopsy specimens before treatment. Fifty-seven out of 59 patients (97%) were locally advanced 
cancers with stages IIIA to IVA. She prepared 8 to 10 slides of 5 µm FFPE tissues, and scratched the tissues from the 
slides into an autoclaved tube using sterile surgical blades. She used the blackPREP DNA Kit (GenoStaff, Tokyo, 
Japan) for DNA extraction according to the manufacturer’s instructions. DNA quality and concentration were 
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examined by Nanodrop. The isolated DNAs were submitted to Eurofins Genomics (Tokyo, Japan) for direct 
sequencing. The author used BioLign software (version 4.0.6.2, http://en.bio-soft.net/) to look for the presence of 
mutations.  
Clinicopathological data and patient survival were compared according to PIK3CA mutational status. She further 
performed cell viability assay examining the effect of a PI3-kinase inhibitor copanlisib (BAY80-6946) in combination 
with cisplatin on cell proliferation of CaSki cells harboring PIK3CA mutation. Cisplatin was purchased from Wako 
(Osaka, Japan). Copanlisib was purchased from LKT Laboratories (St. Paul, MN, USA). Cells in the log growth 
phase were seeded on 96-well plates at 2,000 cells per well. Twenty-four hours later, cells were treated with increasing 
doses of cisplatin (0.01-100 µM), copanlisib (1-10,000 nM), or cisplatin plus copanlisib. Cellular proliferation was 
monitored after 72 hours of treatment using a WST-1 assay as follows. WST-1 (Dojindo, Kumamoto, Japan) and 1-
methoxy PMS (Dojindo) were added to the wells and incubated for 4 hours, and then the absorbance at 450 nm was 
measured and normalized relative to the absorbance of cell cultures treated with DMSO alone. The mean and SD 
were obtained from independent 3 experiments. 
[Results]  PIK3CA mutation was found in 7 out of 59 patients (12%). Five (71%) of the mutations were mapped on 
the helical domain, and one (14%) on the kinase domain of the p110α protein. No significant clinical differences 
were observed according to PIK3CA mutational status. Patients with wild-type PIK3CA showed significantly 
improved cancer-specific survival as compared with mutated patients (p=0.044). Subsequent survival analyses 
revealed that PIK3CA mutation was a significant prognostic factor for poor overall survival (multivariate adjusted 
HR, 3.88; 95% CI, 1.28-11.78; p=0.017) and cancer-specific survival (multivariate adjusted HR, 3.60; 95% CI, 1.19-
10.95; p=0.024). Next, she performed cell viability assay to examine the effect of a PI3-kinase inhibitor copanlisib 
(BAY80-6946) in combination with cisplatin on cell proliferation of CaSki cells harboring heterozygous PIK3CA 
mutation. By treatment with copanlisib in combination with cisplatin, IC50 decreased from 7.32 μM to 6.04 μM. From 
the numerical value of the calculated Combination Index, this effect was found to be synergistic rather than additive 
effect. 
 [Discussion and Conclusion] The mutational analysis of this study found PIK3CA mutations in 12% of the patients, 
which is relatively lower than the results previously reported (13-36%), possibly due to difference in quality of 
samples for DNA extraction, as she used archival FFPE biopsy specimens from patients with mostly locally advanced 
cancers before treatment. Her subsequent survival analyses revealed that patients with mutant PIK3CA had 
significantly worse cancer-specific survival than those with wild type, and that PIK3CA mutation was a significant 
prognostic factor for poor overall and cancer-specific survival. These findings suggest that molecular inhibitors 
targeting the PI3-kinase/AKT pathway may improve the outcome by CCRT in cervical cancers harboring PIK3CA 
mutation, providing significant implications for novel treatment strategy based on precision medicine in the disease. 
 
審査の結果の要旨 
Abstract of assessment result 
（General Comments） 
This study is very challenging and unique, since the author used the real biopsied and surgically resected materials 
fixed by formalin to study the relationship between PIK3CA mutational status and patients’ outcome after CCRT. The 
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conclusion is very clear but this study contains several limitations. First, the total sample size is small, which may 
have also impacted on the small number of PIK3CA mutations found. Secondly, only one cell line, PIK3CA-mutated 
CaSki, was used in the cell viability assay. However, the results and conclusion are almost acceptable and further 
additional experiments are recommended. 
 
 
（Assessment） 
The final examination committee conducted a meeting as a final examination on October 3rd, 2018. The applicant 
provided an overview of dissertation, addressed questions and comments raised during Q&A session. All of the 
committee members reached a final decision that the applicant has passed the final examination. 
 
（Conclusion） 
The final examination committee approved that the applicant is qualified to be awarded Doctor of Philosophy in 
Medical Sciences. 
 
